Cellgram™ (Bone marrow-derived MSCs) for Liver Cirrhosis

Phase 1

Waitlist Available

Led By Juan Gallegos-Orozco, Ph.D

Research Sponsored by Pharmicell Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a cell therapy called Cellgram™ for patients with severe liver damage from alcohol use. The therapy involves injecting cells from the patient's own bone marrow into their liver to help it heal.

Eligible Conditions

Liver Cirrhosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of Serious Adverse Events

Secondary study objectives

Chronic liver disease as assessed by the Child-Pugh score

How well the Liver is functioning

Incidence of Adverse Events

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cellgram™ (Bone marrow-derived MSCs)Experimental Treatment1 Intervention

Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10\^7 cells/10 mL (range: 4.5 x 10\^7 to 5.5 x 10\^7 cells/10 mL) via the hepatic artery.

Do I qualify?Apply below to find out